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Summary
maternal depression and anxiety during 
pregnancy and the early years of an infant's life 
cause substantial problems to the mother, her 
infant and her family. Suicide is an ever-present 
risk with depression along with adverse effects 
on infant growth and birth weight. Balancing 
these risks against accumulating evidence of the 
effects of selective serotonin reuptake inhibitors 
on the fetus and infant presents a challenge to 
the treating doctor. Careful explanation to the 
woman and her partner of the risks of both the 
condition and the treatment, using a biological, 
psychological and social treatment approach, is 
likely to provide the most benefit.




Depression in pregnant and lactating women is a common 
problem. In attempting to find the best treatment options for 
these women, doctors work with less knowledge and more risks 
than with other patients. Drug trials always exclude pregnant 
and lactating women and therefore practice is guided by data 
accumulated from clinical experience. Clinicians must consider 
the risk of damage from the medications and the effects of the 
illness itself on both the mother and the baby.
Harmful effects of maternal depression
There is increasing evidence that antenatal and postnatal 
anxiety and depression potentially have enduring effects on 
offspring.
Pregnancy
Although some studies differ, most document maternal 
antenatal depression as causing slightly shorter gestational 
length and lower birth weight in newborns.1 Antenatal anxiety 
has shown a strong association with raised cortisol levels in  
10-year-old offspring, with the potential for increased 
vulnerability to psychopathology in these children.2 Boys whose 
depressed mothers show ambivalence to them in early months 
have increased rates of behavioural problems and learning 
difficulties by the age of five years.3
Lactation
The relationship between postnatal depression and 
breastfeeding is emerging as complex. Women who develop 
postnatal depression are more likely to stop breastfeeding than 
women who are not depressed. Likewise, women who establish 
and maintain breastfeeding are less likely to develop depression 
than women who have difficulties with breastfeeding.
Harmful effects of antidepressants 
Antidepressant use in Australia has changed in the last two 
decades. Tricyclic antidepressants have fallen from favour and 
many have been withdrawn. Their adverse effects and risk 
of fatality from overdose make them hazardous. However, 
some doctors continue to prescribe them after considering 
the risks and the benefits. There have been few documented 
problems arising from their use, but this is perhaps due to lack 
of extensive research. A small study on the use of dothiepin in 
lactation suggested better outcomes for children of depressed 
mothers taking the drug compared to those whose mothers 
chose no medication.4 Case reports suggest that doxepin may 
be harmful to infants and should be avoided in breastfeeding.5
Data on mirtazapine are sparse and therefore this drug should 
not be used as a first-line treatment in pregnancy. Recent 
work cautiously suggests that levels of mirtazapine are low in 
breastfed infants. 
Venlafaxine use in early pregnancy has been associated 
with increased rates of spontaneous abortion but not fetal 
abnormality. There are also now many case reports of neonatal 
effects so it should be used with great caution in pregnancy. 
Venlafaxine has the potential to accumulate in the breastfed 
baby with prolonged treatment.6
Drugs used to treat bipolar depression include sodium valproate 
which is highly teratogenic and is best avoided in the first 
trimester. However, it is probably safe to use during lactation. 
Lithium may also cause fetal abnormalities and is generally 
advised against in early pregnancy and during lactation. 
However, a recent review of its use in the first trimester has 
shown lower rates of cardiac abnormalities than previously 
documented. Its use in lactation has suggested it is relatively 
safe in compliant mothers with healthy babies.7 Infants must be 
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and thyroid function. Specialist advice is highly recommended 
with lithium. This is also the case for lamotrigine.
SSRIs during pregnancy
First trimester: Early prospective trials on SSRIs suggested they 
were safe with no teratogenic effects. However, recent data have 
challenged this and suggest a small increase in birth defects. 
These results were not statistically significant and should be 
interpreted with caution.8,9 Paroxetine has been associated 
with cardiovascular abnormalities10, although recent analysis 
suggests this risk is only at doses greater than 25 mg per day.11
Second and third trimesters: Recent studies show a small but 
significant risk of shorter gestational length and lower birth 
weight in infants of mothers who used SSRIs in later pregnancy 
even compared to babies of untreated mothers with depression.1
Third trimester: Increases in mild respiratory distress, irritability 
and feeding problems have been observed in infants of mothers 
taking SSRIs in late pregnancy. Some but not all research 
suggests that paroxetine may cause more neonatal difficulties.12 
These effects are self-limiting and have generally settled by 14 
days. It is unclear whether these neonatal effects are withdrawal 
or toxic effects.13 There have also been reports of persistent 
pulmonary hypertension of the newborn14 and possibly 
intraventricular haemorrhage.12
SSRIs during lactation
Many SSRIs are highly protein bound and little drug is 
transferred from the mother to the infant during lactation. 
We can therefore be more confident in prescribing SSRIs in 
lactation.5 However, there is individual variability in infant 
levels of SSRIs and there are occasional case reports describing 
adverse effects.15 Less data are available on the use of other 
antidepressant drugs during lactation. 
So what is a doctor to do?
When a woman presents early in pregnancy with depression 
a very careful assessment should be made, preferably with 
her partner or other family member as additional historian. An 
assessment of risk of self-harm or suicide is vital. Other risks 
such as poor antenatal care are increased with depression. 
Once safety issues and general self-care have been addressed, 
a biological, psychological and social treatment plan should 
be explored relating to the patient's needs and wishes, and 
the severity of the depression. Sufficient information should 
be provided to the patient so they can make an informed 
decision about their treatment. Careful documentation of these 
discussions is important for medicolegal reasons. 
Pre-conception counselling for women already taking 
antidepressants must explore the relative risks of the depression 
itself compared to the risks of using antidepressants in 
pregnancy. Anxiety about medication use in pregnancy may 
be high. For a woman whose depression has receded, a trial 
of slow cessation of medication before conception may be 
successful, but her mental state should be monitored in case  
of a relapse.
Unplanned conceptions for women on antidepressants can 
cause alarm and some women will abruptly cease their 
medication. Unfortunately, up to 75% of women who do so 
may develop a recurrence of their depression before delivery.13 
Careful reassessment of relative risks will reassure many 
women that continuation of their medication is appropriate. 
If a pregnant woman decides to continue taking the drug, 
doctors should be aware that pharmacokinetics change during 
pregnancy. In the event of a relapse, a woman might need 
higher doses of many drugs including SSRIs to maintain clinical 
improvement.
Later in pregnancy, concerns over neonatal toxicity and 
withdrawals guide some doctors to lower SSRI doses until 
after delivery. Anecdotally, many women can manage this well, 
provided good psychosocial support is available. Some women 
will choose to continue on current doses with support, and 
appropriate management of the neonate.
Which antidepressant to use?
Experts differ in their assessments of the relative risks of the 
antidepressants, but in general, SSRIs are preferred to tricyclic 
antidepressants, combined serotonin and noradrenaline 
reuptake inhibitors and mirtazapine. Every antidepressant 
has been associated with some neonatal effects, and different 
studies show differing results. The data on paroxetine in higher 
doses cause concern.11 While some perinatal psychiatrists 
prefer fluoxetine with its longer half-life and potential for slower 
neonatal withdrawal effects, many prefer the shorter-acting 
SSRIs, either citalopram, fluvoxamine or sertraline as the 
maternal response may be faster. 
useful sources of information 
It is essential to frequently update information about best 
practice in this area as new information rapidly changes 
practice. Reliable websites such as the Organisation of 
Teratology Information Specialists (OTIS) (www.otispregnancy.
org) and the Canadian www.motherisk.org are valuable to both 
doctors and patients. Most large Australian obstetric facilities 
also provide a pharmacy information service (see box), and if  
in doubt, a telephone call is appropriate. Telephone advice  
from a psychiatrist can be obtained privately or through  
GP PsychSupport on 1800 200 588. Pharmaceutical companies 
may have additional data about the effects of antidepressants 
on pregnancy and lactation.
Conclusion
The risks of the depression and its consequences must be 
weighed against the risks of the medications to both mother and |   Volume 30   |   NumBeR 5  |  oCToBeR 2007  127
infant during the different phases of pregnancy and lactation. 
Careful history taking, close monitoring and good psychosocial 
care may be sufficient for many women with depression 
during pregnancy. When antidepressants are needed, the baby 
should be monitored postnatally for feeding, neurological and 
respiratory difficulties. Prescription of SSRIs postnatally appears 
less hazardous than in antenatal use, and potentially of benefit 
to mother and child.
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Self-test questions
The following statements are either true or false  
(answers on page 135)
3. It is safe to prescribe sodium valproate during early 
pregnancy.
4. Generally, SSRIs are safe to use during lactation.
Pregnancy drug information centres
New South Wales
MotherSafe
Tel:  (02) 9382 6539 / 1800 647 848 (toll free for NSW callers)
Queensland
Queensland Drug Information Centre (health professionals)
Tel:  (07) 3636 7098 
South Australia
Women's and Children's Hospital
Tel:  (08) 8161 7222
Victoria
Royal Women's Hospital
Tel:  (03) 9344 2277
Western Australia
Women's & Newborn Health Service
Tel:  (08) 9340 2723